NCF TeamAug 6, 20242 min readNew Progress in Treatment Options...Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients...
NCF TeamApr 23, 20241 min readBreaking News: Lutathera® PRRT Now Approved for Adolescents (12-17 year olds)On April 23, 2024, the Food and Drug Administration approved lutetium Lu 177 dotatate (Lutathera®, Advanced Accelerator Applications USA,...
